These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25550273)

  • 1. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II).
    Hasinoff BB; Wu X; Yadav AA; Patel D; Zhang H; Wang DS; Chen ZS; Yalowich JC
    Biochem Pharmacol; 2015 Feb; 93(3):266-76. PubMed ID: 25550273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II).
    Hasinoff BB; Yadav AA; Patel D; Wu X
    J Inorg Biochem; 2014 Aug; 137():22-30. PubMed ID: 24798374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II).
    Yadav AA; Patel D; Wu X; Hasinoff BB
    J Inorg Biochem; 2013 Sep; 126():1-6. PubMed ID: 23707906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells.
    Nagai M; Vo NH; Shin Ogawa L; Chimmanamada D; Inoue T; Chu J; Beaudette-Zlatanova BC; Lu R; Blackman RK; Barsoum J; Koya K; Wada Y
    Free Radic Biol Med; 2012 May; 52(10):2142-50. PubMed ID: 22542443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LC-MS/MS and density functional theory study of copper(II) and nickel(II) chelating complexes of elesclomol (a novel anticancer agent).
    Wu L; Zhou L; Liu DQ; Vogt FG; Kord AS
    J Pharm Biomed Anal; 2011 Jan; 54(2):331-6. PubMed ID: 20933353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, crystallographic characterization and electrochemical property of a copper(II) complex of the anticancer agent elesclomol.
    Vo NH; Xia Z; Hanko J; Yun T; Bloom S; Shen J; Koya K; Sun L; Chen S
    J Inorg Biochem; 2014 Jan; 130():69-73. PubMed ID: 24176921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two new ternary complexes of copper(II) with tetracycline or doxycycline and 1,10-phenanthroline and their potential as antitumoral: cytotoxicity and DNA cleavage.
    Silva PP; Guerra W; Silveira JN; Ferreira AM; Bortolotto T; Fischer FL; Terenzi H; Neves A; Pereira-Maia EC
    Inorg Chem; 2011 Jul; 50(14):6414-24. PubMed ID: 21692452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines.
    Robson CN; Hoban PR; Harris AL; Hickson ID
    Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elesclomol-Copper Nanoparticles Overcome Multidrug Resistance in Cancer Cells.
    Wang Q; Huang CH; Wibowo FS; Amin R; Shen J; Li F; Babu RJ
    ACS Appl Mater Interfaces; 2024 Mar; 16(11):13509-13524. PubMed ID: 38466024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
    Sullivan DM; Latham MD; Ross WE
    Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.
    Qu Y; Wang J; Sim MS; Liu B; Giuliano A; Barsoum J; Cui X
    Breast Cancer Res Treat; 2010 Jun; 121(2):311-21. PubMed ID: 19609669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dinuclear copper(I) complexes containing cyclodiphosphazane derivatives and pyridyl ligands: synthesis, structural studies, and antiproliferative activity toward human cervical and breast cancer cells.
    Balakrishna MS; Suresh D; Rai A; Mague JT; Panda D
    Inorg Chem; 2010 Oct; 49(19):8790-801. PubMed ID: 20812680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic cell death: a possible key event in mediating the in vitro anti-proliferative effect of a novel copper(II) complex, [Cu(4-Mecdoa)(phen)(2)] (phen=phenanthroline, 4-Mecdoa=4-methylcoumarin-6,7-dioxactetate), in human malignant cancer cells.
    Thati B; Noble A; Creaven BS; Walsh M; Kavanagh K; Egan DA
    Eur J Pharmacol; 2007 Aug; 569(1-2):16-28. PubMed ID: 17585902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evaluation of the anti-cancer drug elesclomol that forms a redox-active copper chelate as a potential anti-tubercular drug.
    Ngwane AH; Petersen RD; Baker B; Wiid I; Wong HN; Haynes RK
    IUBMB Life; 2019 May; 71(5):532-538. PubMed ID: 30698324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.
    Hasinoff BB; Wu X; Yalowich JC; Goodfellow V; Laufer RS; Adedayo O; Dmitrienko GI
    Anticancer Drugs; 2006 Aug; 17(7):825-37. PubMed ID: 16926632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H; Wu X; Yalowich JC; Hasinoff BB
    Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial electron transport is the cellular target of the oncology drug elesclomol.
    Blackman RK; Cheung-Ong K; Gebbia M; Proia DA; He S; Kepros J; Jonneaux A; Marchetti P; Kluza J; Rao PE; Wada Y; Giaever G; Nislow C
    PLoS One; 2012; 7(1):e29798. PubMed ID: 22253786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.